V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

AbbVie Executive Compensation (FY25)

ABBV · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Robert Michael
Latest say-on-pay support
=
May 8, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on AbbVie

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): May 12, 2026
13 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
AbbVie brief$1,500Get the executive brief
Velarion Member, one year
402 figures on this page: 393 cited to the filing that reported them, 9 calculated from figures it prints. See the citations

More on AbbVie

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Robert Michael: $18,492,517 → $32,530,984 (75.9% higher)
CEO pay ratio: 138:1 → 192:1 (39.1% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is AbbVie's chief executive and what were they paid?
Robert Michael, Chairman of the Board and Chief Executive Officer, received $32,530,984 in total compensation for fiscal 2025. Compared with the $18,492,517 reported for fiscal 2024, Michael's total was 75.9% higher.
What was AbbVie's say-on-pay result?
The say-on-pay proposal drew 93.8% support at the meeting held May 8, 2026 for fiscal 2025.
Which companies are in AbbVie's peer group?
The disclosed peer group includes Amgen, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc. and GlaxoSmithKline plc, among others.
What is AbbVie's chief executive pay ratio?
The company reported a chief executive pay ratio of 192:1 for fiscal 2025, against median employee compensation of $169,019.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Gonzalez
Chairman of the Board and Chief Executive Officer
◇—◇◇◇◇◇◇
Robert Michael
Chief Executive Officer
◇—◇◇◇◇◇◇
Jeffrey Stewart
Executive Vice President, Chief Commercial Officer
◇—◇◇◇◇◇◇
Azita Saleki-Gerhardt
Executive Vice President, Chief Operations Officer
◇—◇◇◇◇◇◇
Scott Reents
Executive Vice President, Chief Financial Officer
◇—◇◇◇◇◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Gonzalez
Executive Chairman of the Board
◇◇◇◇◇◇◇◇
Jeffrey Stewart
Executive Vice President, Chief Commercial Officer
◇—◇◇◇◇◇◇
Robert Michael
Chairman of the Board and Chief Executive Officer
◇—◇◇◇◇◇◇
Scott Reents
Executive Vice President, Chief Financial Officer
◇—◇◇◇◇◇◇
Azita Saleki-Gerhardt
Executive Vice President, Chief Operations Officer
◇—◇◇◇◇◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Gonzalez
Executive Chairman of the Board
◇◇◇◇◇◇◇◇
Robert Michael
Chairman of the Board and Chief Executive Officer
◇—◇◇◇◇◇◇
Jeffrey Stewart
Executive Vice President, Chief Commercial Officer
◇—◇◇◇◇◇◇
Scott Reents
Executive Vice President, Chief Financial Officer
◇—◇◇◇◇◇◇
Timothy Richmond
Executive Vice President, Chief Human Resources Officer
◇◇◇◇◇◇◇◇
Azita Saleki-Gerhardt
Executive Vice President, Chief Operations Officer
◇—◇◇◇◇◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Michael
Chairman of the Board and Chief Executive Officer
◇—◇◇◇◇◇◇
Jeffrey Stewart
Executive Vice President, Chief Commercial Officer
◇—◇◇◇◇◇◇
Scott Reents
Executive Vice President, Chief Financial Officer
◇—◇◇◇◇◇◇
Azita Saleki-Gerhardt
Executive Vice President, Chief Operations Officer
◇—◇◇◇◇◇◇
Roopal Thakkar
Executive Vice President, Research & Development and Chief Scientific Officer
◇—◇◇◇◇◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Azita Saleki-GerhardtPSU◇◇◇—◇—◇
Azita Saleki-GerhardtPSU◇◇◇—◇—◇
Azita Saleki-GerhardtOPTION◇——◇—◇◇
Jeffrey StewartPSU◇◇◇—◇—◇
Jeffrey StewartPSU◇◇◇—◇—◇
Jeffrey StewartOPTION◇——◇—◇◇
Richard GonzalezOPTION◇—————◇
Robert MichaelPSU◇◇◇—◇—◇
Robert MichaelOPTION◇——◇—◇◇
Robert MichaelPSU◇◇◇—◇—◇
Roopal ThakkarPSU◇◇◇—◇—◇
Roopal ThakkarPSU◇◇◇—◇—◇
Roopal ThakkarOPTION◇——◇—◇◇
Scott ReentsPSU◇◇◇—◇—◇
Scott ReentsPSU◇◇◇—◇—◇
Scott ReentsOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Robert MichaelOption◇—◇—
PSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
PSU◇◇——
Jeffrey StewartOption◇—◇—
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
Azita Saleki-GerhardtPSU◇◇——
Option◇—◇—
PSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
Roopal ThakkarOption◇—◇—
PSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
PSU◇◇——
Scott ReentsPSU◇◇——
Option◇—◇—
PSU◇◇——
Option◇—◇—
PSU◇◇——
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Azita Saleki-Gerhardt
Executive Vice President, Chief Operations Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Change-in-control multiple◇
Benefits continuation on change in control◇
Excise tax treatment◇
Jeffrey Stewart
Executive Vice President, Chief Commercial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Change-in-control multiple◇
Benefits continuation on change in control◇
Excise tax treatment◇
Robert Michael
Chairman of the Board and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Change-in-control multiple◇
Benefits continuation on change in control◇
Roopal Thakkar
Executive Vice President, Research & Development and Chief Scientific Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Change-in-control multiple◇
Benefits continuation on change in control◇
Excise tax treatment◇
Scott Reents
Executive Vice President, Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Change-in-control multiple◇
Benefits continuation on change in control◇
Excise tax treatment◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard A. Gonzalez
—◇◇—◇◇◇
Robert J. Alpern
◇◇——◇◇◇
Roxanne S. Austin
Lead independent director
◇◇———◇◇
Melody B. Meyer
◇◇———◇◇
Frederick H. Waddell
◇◇———◇◇
Brett J. Hart
◇◇———◇◇
Thomas C. Freyman
◇◇———◇◇
Edward J. Rapp
◇◇———◇◇
William H.L. Burnside
◇◇———◇◇
Jennifer L. Davis
◇◇———◇◇
Rebecca B. Roberts
◇◇———◇◇
Susan E. Quaggin
◇◇—◇◇—◇
Thomas J. Falk
◇◇———◇◇
Glenn F. Tilton
◇◇———◇◇
Robert A. Michael served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Nominating and governance chair◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Amgen, Inc. AMGN
  • Bristol-Myers Squibb Company BMY
  • Eli Lilly and Company LLY
  • Gilead Sciences, Inc. GILD
  • GlaxoSmithKline plc GSK
  • Johnson & Johnson JNJ
  • Merck & Company, Inc. MRK
  • Novartis AG NVS
  • Pfizer Inc. PFE

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 8, 2026=◇◇◇
2024May 9, 2025=◇◇◇
2022May 5, 2023=◇◇◇
2021May 6, 2022=◇◇◇
2020May 7, 2021=◇◇◇
2019May 8, 2020=◇◇◇
2018May 3, 2019=◇◇◇
2017May 4, 2018=◇◇◇
2016May 5, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Robert Michael (Chairman of the Board and Chief Executive Officer), FY2025 total compensation $32,530,984 (base salary $1,700,000) [exec_comp, SEC accession 0001104659-26-033387, filed 2026-03-23]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when AbbVie files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact AbbVie disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where AbbVie sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether AbbVie's disclosed peer group is defensible, who names AbbVie back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
402 figures on this page: 393 cited to the filing that reported them, 9 calculated from figures it prints.
393 cited to the filing
9 calculated from the filing

Documents cited

  1. 0001104659-26-059484
    Abstain 1,522,575,012 23,766,564 2,136,457 (3) The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers, as follows: For Against Abstain Broker Non-Votes
  2. 0001104659-26-033387
    2025 Grants of Plan-Based Awards · 2025 Outstanding Equity Awards at Fiscal Year End · Compensation Discussion and Analysis · DIRECTOR COMPENSATION · and 2 more sections
  3. 0001104659-25-047402
    Abstain 1,498,390,498 27,184,089 2,389,411 (3) The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers, as follows: For Against Abstain Broker Non-Votes
  4. 0001558370-25-003537
    Summary Compensation Table
  5. 0001558370-24-003496
    Summary Compensation Table
  6. 0001104659-23-058520
  7. 0001558370-23-004204
    Summary Compensation Table
  8. 0001104659-22-058862
  9. 0001104659-21-063958
  10. 0001104659-20-060256
  11. 0001104659-19-027194
  12. 0001104659-18-031358
  13. 0001104659-17-031175
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “AbbVie executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ABBV (accessed 2026).
Short form: data: Velarion

The paid brief for AbbVie

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about AbbVie and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers AbbVie discloses

The companies named in ABBV's own disclosed peer group.

Amgen, Inc.Bristol-Myers Squibb CompanyEli Lilly and CompanyGilead Sciences, Inc.Johnson & JohnsonMerck & Company, Inc.Pfizer Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy